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The morpho-pathological correlate of diastolic dysfunction is reduced myocardial compliance due to cardiac fibrosis, whereby normal myocardial architecture is disrupted by excessive and disordered deposition of extracellular matrix and collagen. 4 Myofibroblasts, the main players in this fibrotic process, can be derived from expansion and activation of resident tissue fibroblasts, from migration of bone marrow-derived circulating fibrocytes, and from endothelialto-mesenchymal transition (EndoMT). 5 Similar to epithelial-to-mesenchymal transition, endothelial-to-mesenchymal transition is a complex phenomenon in which endothelial cells acquire a mesenchymal phenotype, expressing mesenchymal markers, such as ␣-smooth muscle actin and type I collagen, instead of vascular endothelial cadherin. In the embryo, endothelial-to-mesenchymal transition is necessary for normal valvular and septal morphogenesis: In fact, the formation of the atrio-ventricular endocardial cushion is dependent on the differentiation of endothelial cells into mesenchymal cells that invade the cardiac jelly. 6 The principal inducer of this process is transforming growth factor (TGF)-␤, a multifunctional growth factor that signals via a classical pathway after binding to TGF-␤ type 2 receptor, activating TGF-␤ type 1 receptor and Smad-mediated transcriptional events (in particular those of Smad 2/3), but also via a Smad-independent signaling pathway, with the direct involvement of TGF-␤-activated kinase 1. 7 TGF-␤ also up-and downregulates the expression of numerous microRNAs, many of which have been extensively investigated.
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Kumarswamy et al 8 show in vitro and in vivo that microRNA-21 (miR-21) is involved in TGF-␤-induced endothelial-to-mesenchymal transition via a PTEN/Aktdependent pathway. miR-21, which has been implicated in human tumorigenesis and progression, is upregulated by TGF-␤. In the endothelium, this growth factor increases expression of both primary and mature miR-21: after exposure to TGF-␤, mature miR-21 expression is much higher in comparison with the primary transcript, an effect probably related to enhanced Smad-mediated processing of the primary precursor of miR-21.
The first report of a role for miR-21 in cardiac pathology was conducted on a murine model of pressure-overloadinduced HF: Thum et al 9 showed that miR-21 is a critical regulator of extracellular signal-regulated kinase/mitogen-activated protein kinase activity in cardiac fibroblasts, enhancing fibrosis by via inhibition of Sprouty 1. Regarding other organs, Zhong et al 10 demonstrated that Smad3 signaling increases expression of miR-21 in the kidney to promote renal fibrosis in response to TGF-␤1: Interestingly, Smad2 and Smad3 differentially regulated the post-transcriptional modifications of miR-21, Smad2 being a negative regulating factor for miR-21. TGF-␤1 was also shown to be central mediator of fibrosis in the lung and, therefore, the induction of miR-21 by TGF-␤1 may represent a potential therapeutic target. 11 Liu et al 12 showed that in mice treated with bleomycin, an inducer of pulmonary fibrosis, enhanced miR-21 expression was primarily localized to ␣-smooth muscle actin ϩ fibroblasts; a concomitant decrease in the expression of Smad7, a negative regulator of lung fibrosis, contributed to the profibrogenesis mechanism of miR-21.
The above results, obtained in different organs-heart, lung, and kidney 9,10,12 -concur in attributing miR-21 a pathological role in fibrosis. Moreover, knockdown of miR-21 was reported to significantly reduce the number of ␣-smooth muscle actin ϩ interstitial myofibroblasts and lessen interstitial collagen type I and fibronectin, hence, blunting renal fibrosis. 10 Therefore, this microRNA may be a promising target for the therapy of fibrotic diseases.
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